Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RS 5614

Next Previous
X
Search
Drug Profile

RS 5614

Alternative Names: RS-5614; TM-5614

Latest Information Update: 29 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Renascience
  • Developer Akita University; Hiroshima University; Renascience; Tohoku University; Tokai University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic myeloid leukaemia
  • Phase II COVID 2019 infections; Haemangiosarcoma; Interstitial lung diseases; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 20 Feb 2024 Phase-II clinical trials in Chronic myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Japan (PO), prior to February 2024
  • 20 Feb 2024 Phase-II clinical trials in COVID-2019 infections in USA, Turkey (PO), prior to February 2024 (Renascience pipeline, February 2024)
  • 20 Feb 2024 Phase-II clinical trials in Haemangiosarcoma (Combination therapy, Second-line therapy or greater) in Japan (PO), prior to February 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top